DPP4 and diabetes mellitus: Both bedtime NPH insulin and incretin-based therapy with dipeptidyl peptidase 4 (DPP4) inhibitors are recommended by the American Diabetes Association for use in selected populations, particularly in older adults and individuals in low-resource settings.